MapLight Therapeutics
MPLT · Nasdaq · United States
Share price · MPLT
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when MPLT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 6 Nov 2026+11.4%
Nothing announced by MPLT that day or the session before.
- 2 Nov 2026-10.6%
Nothing announced by MPLT that day or the session before.
- 29 Jul 2026+22.0%
Nothing announced by MPLT that day or the session before.
- 28 Jul 2026+24.3%
- 27 Jul 2026-72.9%
- 11 May 2026+9.8%
Nothing announced by MPLT that day or the session before.
- 4 May 2026-6.8%
Nothing announced by MPLT that day or the session before.
- 22 Apr 2026+16.3%
Nothing announced by MPLT that day or the session before.
- 9 Apr 2026+21.3%
Nothing announced by MPLT that day or the session before.
Share of unusual movement by asset
For each asset, the share of MPLT's own-move activity since 28 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Betovumeline/fesoterodine (ML-007C-MA)events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 49% |
| Other company news (earnings, financing, releases naming no asset) | — | 3% |
| Sessions with no dated event | — | 48% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Muscarinic M1 and M4 receptors (agonist)Small molecule | Alzheimer's DiseaseSchizophreniaAlzheimer's Disease Psychosis |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (1)
December 2027 (1)
What to watch
2029 (1)
March 2029 (1)
What to watch
2030 (1)
February 2030 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (6)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $53M | $72M+ $233M short-term inv. | $60M-$45M operating cash flow | report ↗ |
View 5 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | — | $54M | $56M+ $254M short-term inv. | $61M-$51M operating cash flow | report ↗ |
| 2025-Q3 | — | $27M | $64M+ $163M short-term inv. | $29M-$32M operating cash flow | report ↗ |
| 2025-Q2 | — | $27M | — | $30M-$34M operating cash flow | report ↗ |
| 2025-Q1 | — | $20M | — | $22M-$26M operating cash flow | report ↗ |
| 2024-Q3 | — | $17M | — | $19M | report ↗ |
Annual history (2 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $138M | $47M+ $258M short-term inv. | $40M-$138M operating cash flow | report ↗ |
MapLight Therapeutics reported no revenue for 2025. R&D expense was $138.35M, up 101.9% YoY from $68.52M, and the company ended the year with $453.1M in cash, cash equivalents and investments. Full-year net loss was $161.15M, compared with $77.6M in 2024.
The company expects its cash position to fund operations through 2027. It guided to Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia reaching target enrollment of 300 patients in April 2026, with topline results expected in the third quarter of 2026; the Phase 2 IRIS trial of ML-004 for autism spectrum disorder has completed enrollment, with topline results also expected in the third quarter of 2026. FDA Fast Track designation was granted for ML-007C-MA for Alzheimer’s disease psychosis, with Phase 2 VISTA topline results expected in the second half of 2027, and the pipeline was expanded with the next-generation ML-055 M1/M4 muscarinic agonist program, with candidate nomination expected in 2026.
View 1 more year
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $69M | $38M+ $71M short-term inv. | $19M-$79M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 10 purchases ($66.2M), 145 sales ($30.2M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-15 | Kroeger Christopher A. · director, Chief Executive Officer | Open-market sale | 73,691 | $8.08 | $595K | Form 4 |
| 2026-10-15 | Foff Erin Pennock · Chief Medical Officer | Open-market sale | 15,355 | $8.08 | $124K | Form 4 |
| 2026-10-15 | Hanson Kristopher · General Counsel | Open-market sale | 9,020 | $8.08 | $73K | Form 4 |
| 2026-10-15 | Lillie James Woodruff · Chief Scientific Officer | Open-market sale | 11,513 | $8.08 | $93K | Form 4 |
| 2026-10-15 | GILLIS JONATHAN · CAO and Interim CFO | Open-market sale | 10,167 | $8.08 | $82K | Form 4 |
| 2026-10-15 | Kreitzer Anatol · Chief Discovery Officer | Open-market sale | 12,248 | $7.84 | $96K | Form 4 |
| 2026-09-16 | Hanson Kristopher · General Counsel | Open-market sale | 16,509 | $11.67 | $193K | Form 4 |
| 2026-08-17 | Kroeger Christopher A. · director, Chief Executive Officer | Award / grant | 23,145 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 81 reporting institutions held 24.8M shares ($445.0M, 58.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | NOVO HOLDINGS A/S | 3,686,622 | $74.9M |
| 2 | FCPM III SERVICES B.V. | 3,226,400 | $65.6M |
| 3 | GOLDMAN SACHS GROUP INC | 1,994,873 | $40.6M |
| 4 | BlackRock, Inc. | 1,339,731 | $27.2M |
| 5 | Blue Owl Capital Holdings LP | 1,005,929 | $20.5M |
| 6 | Nan Fung Group Holdings Ltd | 971,253 | $19.7M |
| 7 | 5AM Venture Management, LLC | 950,011 | $19.3M |
| 8 | Sanofi | 912,041 | $18.5M |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 719,820 | $14.6M |
| 10 | Pivotal bioVenture Partners Investment Advisor LLC | 611,447 | $12.4M |
| 11 | Velan Capital Investment Management LP | 492,893 | $10.0M |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 481,201 | $9.8M |
| 13 | Siren, L.L.C. | 450,000 | $9.1M |
| 14 | Vestal Point Capital, LP | 420,000 | $8.5M |
| 15 | ADAR1 Capital Management, LLC | 374,909 | $7.6M |